Literature DB >> 31508183

TREATMENT OF CUSHING'S SYNDROME : WHAT PLACE FOR MEDICAL TREATMENT?

O Chabre1, J Cristante1.   

Abstract

Surgery plays a major role as a first-line treatment of the different etiologies of Cushing's syndrome (CS) and bilateral adrenalectomy (BA) is extremely effective as a second line, so that there seems to be little room for medical treatment (MT). However, during the past years several drugs acting either on ACTH secretion or cortisol synthesis have been developed, so that MT of CS might be reassessed. After briefly analyzing the efficiency and tolerance of surgical and medical treatments of CS we try to distinguish consensual and controversial indications for MT. We believe the former include "pre-operative treatment" in rare patients in whom the severity of CS is likely to increase the risks of surgery; "inoperability" for rare patients who cannot be operated even when CS is controlled and "surgical failure or recurrence", mainly in patients Cushing's disease (CD) not in remission after TSS. Controversial indications include "unavailability of an expert surgeon", which we believe does not make sense when the cost of MT is taken into consideration. Finally in patients with the "surgical failure or recurrence" indication the balance between efficacy and side effects of MT should be balanced with the efficacy and side effects of BA.

Entities:  

Keywords:  Cushing’s; pituitary surgery

Year:  2019        PMID: 31508183      PMCID: PMC6711638          DOI: 10.4183/aeb.2019.237

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  31 in total

1.  Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.

Authors:  E Baudin; G Pellegriti; M Bonnay; A Penfornis; A Laplanche; G Vassal; M Schlumberger
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

2.  No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.

Authors:  Luigi Maione; Cyril Garcia; Amir Bouchachi; Nozha Kallel; Patrick Maison; Sylvie Salenave; Jacques Young; Patrick Assayag; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2012-06-21       Impact factor: 5.958

3.  Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.

Authors:  Peter Kamenický; Céline Droumaguet; Sylvie Salenave; Anne Blanchard; Christel Jublanc; Jean-François Gautier; Sylvie Brailly-Tabard; Sophie Leboulleux; Martin Schlumberger; Eric Baudin; Philippe Chanson; Jacques Young
Journal:  J Clin Endocrinol Metab       Date:  2011-07-13       Impact factor: 5.958

4.  The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.

Authors:  Andrea M Isidori; Gregory A Kaltsas; Carlotta Pozza; Vanni Frajese; John Newell-Price; Rodney H Reznek; Paul J Jenkins; John P Monson; Ashley B Grossman; G Michael Besser
Journal:  J Clin Endocrinol Metab       Date:  2005-11-22       Impact factor: 5.958

5.  Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome.

Authors:  A Lacroix; N Ndiaye; J Tremblay; P Hamet
Journal:  Endocr Rev       Date:  2001-02       Impact factor: 19.871

Review 6.  Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review.

Authors:  O Steichen; F Zinzindohoué; P-F Plouin; L Amar
Journal:  Horm Metab Res       Date:  2012-01-13       Impact factor: 2.936

7.  A 12-month phase 3 study of pasireotide in Cushing's disease.

Authors:  Annamaria Colao; Stephan Petersenn; John Newell-Price; James W Findling; Feng Gu; Mario Maldonado; Ulrike Schoenherr; David Mills; Luiz Roberto Salgado; Beverly M K Biller
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

Review 8.  The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.

Authors:  Frederic Castinetti; Thierry Brue; Bernard Conte-Devolx
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-08       Impact factor: 3.243

9.  Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health.

Authors:  Ioannis Ilias; David J Torpy; Karel Pacak; Nancy Mullen; Robert A Wesley; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2005-05-24       Impact factor: 5.958

Review 10.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Authors:  B M K Biller; A B Grossman; P M Stewart; S Melmed; X Bertagna; J Bertherat; M Buchfelder; A Colao; A R Hermus; L J Hofland; A Klibanski; A Lacroix; J R Lindsay; J Newell-Price; L K Nieman; S Petersenn; N Sonino; G K Stalla; B Swearingen; M L Vance; J A H Wass; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

View more
  3 in total

1.  A Close Encounter - Left Pneumonia and Pancreatic Tail Fistula after Laparoscopic Left Adrenalectomy.

Authors:  O Enciu; E A Toma; C Badiu; A Miron
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Oct-Dec       Impact factor: 0.877

2.  SURGICAL MANAGEMENT OF THE ADRENAL GLAND TUMORS - SINGLE CENTER EXPERIENCE.

Authors:  A M Mușină; I Huțanu; D V Scripcariu; M G Aniței; B Filip; M Hogea; I Radu; M M Gavrilescu; A Panuță; M Buna-Arvinte; V G Moraru; V Scripcariu
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

3.  EFFECTIVENESS OF UNILATERAL ADRENALECTOMY IN BILATERAL ADRENAL INCIDENTALOMA PATIENTS WITH SUBCLINICAL HYPERCORTISOLEMIA.

Authors:  N Yilmaz; G Tazegul; R Sari; E Avsar; H Altunbas; M K Balci
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Oct-Dec       Impact factor: 1.104

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.